ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,953 GBX | +5.29% |
|
+9.22% | +12.45% |
| 10:34am | AstraZeneca: strong sales growth in Q1 | CF |
| 10:20am | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
Financials (USD)
| Sales 2024 * | 50.81B | Sales 2025 * | 54.48B | Capitalization | 219B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.71B | Net income 2025 * | 10.26B | EV / Sales 2024 * | 4.7 x |
| Net Debt 2024 * | 19.83B | Net Debt 2025 * | 12.92B | EV / Sales 2025 * | 4.25 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
21.7
x | Employees | 89,900 |
| Yield 2024 * |
2.19% | Yield 2025 * |
2.3% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +5.25% | ||
| 1 week | +9.33% | ||
| Current month | +11.74% | ||
| 1 month | +14.80% | ||
| 3 months | +14.20% | ||
| 6 months | +13.14% | ||
| Current year | +12.57% |
1 week
10 764.00
12 086.00
1 month
10 314.0012 086.00
Current year
9 461.0012 086.00
1 year
9 461.0012 210.00
3 years
7 392.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +12.57% | ||
| 5.17% | 18 M€ | +3.04% | - | |
| 4.89% | 776 M€ | +8.49% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 11,922 | +5.02% | 777 887 |
| 24-04-24 | 11,352 | +0.75% | 3,596,131 |
| 24-04-23 | 11,268 | +0.16% | 3,561,073 |
| 24-04-22 | 11,250 | +2.78% | 3,448,159 |
| 24-04-19 | 10,946 | +0.29% | 1,407,714 |
Delayed Quote London S.E., April 25, 2024 at 04:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
02:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.1
USD
Average target price
161.4
USD
Spread / Average Target
+14.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.57% | 219B | |
| +25.61% | 660B | |
| +24.29% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| -9.61% | 196B | |
| +6.52% | 199B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- AZN Stock
